Affimed Therapeutics (AFMD) PT Lowered to $1 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts AFMD Hot Sheet
Price: $0.18 --0%
Rating Summary:
9 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
9 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Stifel analyst Bradley Canino lowered the price target on Affimed Therapeutics (NASDAQ: AFMD) to $1.00 (from $2.00) while maintaining a Hold rating.
You May Also Be Interested In
- AppLovin Corp (APP) PT Raised to $355 at Piper Sandler
- Charles River Labs (CRL) PT Raised to $352 at RBC Capital
- Materion Corp. (MTRN) PT Lowered to $232; KeyBanc: 'We would be aggressive buyers'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
